Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 124Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 27Leukemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Recurrence 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 9Leukemia, Biphenotypic, Acute 8Hematologic Neoplasms 8Leukemia, Myelomonocytic, Chronic 7Neoplasm, Residual 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6Burkitt Lymphoma 6Neoplasms 5Waldenstrom Macroglobulinemia 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid 4Leukemia, Monocytic, Acute 3GATA2 Deficiency 3Sarcoma, Myeloid 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoglobulin Light-chain Amyloidosis 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2

Interventions

ruxolitinib 2duvelisib 2venetoclax 1Lisaftoclax 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Prolymphocytic, T-Cell × venetoclax × Clear all
NCT06810778 2025-07-15

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡